Sanofi-Aventis Korea to launch rapid-acting insulin glulisine
The company said it has added another diabetes drug to its catalog with the approval of insulin glulisine [rDNA origin] injection, a rapid acting insulin analogu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
